Therapeuticsmd, Inc. · NASDAQ:TXMD
Therapeuticsmd — Q3 2021 Earnings Presentation
22 slides from Therapeuticsmd's earnings presentation, Nov 12, 2021
Slide 1: Building the Premier Women's Health Company Q3 2021 Earnings
Building the Premier Women’s Health Company Q3 2021 Earnings November 11, 2021 Exhibit 99.3
Slide 2: Forward-Looking Statements
Forward-Looking Statements 2 This presentation by TherapeuticsMD, Inc. (referred to as “we,” “our,” or “the Company”) may contain forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating to our objectives, plans and strategies, as well as statem
Slide 3: Announcing: Hugh O'Dowd
TherapeuticsMD ss 1 Announcing: Hugh O’Dowd
Slide 4: Immediate Priorities
Drive top-line growth and overall operating performance Address capital structure to ease restrictive revenue and cash covenants currently in place Immediate Priorities Eliminate $60 million in annual costs in 2022, including the successful divestiture of vitaCare 1 Achieve EBITDA breakeven in the s
Slide 5: 3Q21 Financial Overview
TherapeuticsMD ss 1 2 3Q21 Financial Overview
Slide 6: Quarterly Product Revenue Trends
$24.5 Quarterly Product Revenue (YoY) Quarterly Product Revenue Trends Millions 3Q21 Highlights Total net product revenue increased 41% Q321 vs Q320 ANNOVERA sales increased by 84% on strong volume growth Q321 vs Q320 IMVEXXY net revenue increased by 17% Q321 vs 3Q20 driven by higher net pricing, pa
Slide 7: Financial Results: Comparison 3Q 2021 to 2Q 2021 and 3Q 2020
Financial Results: Comparison 3Q 2021 to 2Q 2021 and 3Q 2020 Net revenue of $25.4M was an increase of $6.1M compared to Q320 Gross margin of 79% decreased from 83% in Q320 Mainly attributable to Q321 margins being negatively impacted by export sales Higher operating expenses in Q321 reflect increase
Slide 8: Q3 2021 Commercial Overview
8 Q3 2021 Commercial Overview
Slide 9: Mark Glickman Career Highlights
Mark Glickman Career Highlights 31 Years in the Pharmaceutical/Device Industry Started with Baxter Healthcare MBA Finance and International Management NYU Stern School of Business Bristol Myers Squibb Lead team on Plavix marketing Launched pivotal CURE Trial Multi-billion dollar product Kos Pharmace
Slide 10: Commercial Vision
Commercial Vision Focus on our Patients and Physicians Environment of Accountability Create a Performance Based Organization that will Execute with Excellence Become the Premier Women’s Healthcare Commercial Organization 10
Slide 11: Barriers to launch are removed
Barriers to launch are removed Opportunities Three differentiated therapeutic options for women Adjusted approach post-covid Transition to an HCP prioritized effort Great team committed to success Significant managed care and other wins 11
Slide 12: ae es
ae es Marketing programs Complex solution orientation overweighted to consumer TherapeuticsM" FoR mvESTOR PRESENTATION PURPOSES ON 4 Managed care was good, albeit in need of optimization
Slide 13: Areas of Immediate Focus
Retarget and redistribute activity to highest decile physicians for all products Focus representatives on solution selling Provide direction, tools and evaluations to create sustainable, consistent growth Accountability message delivered throughout TXMD Areas of Immediate Focus 13 Build confidence a
Slide 14: Results
TherapeuticsMD” For Her: For Life. Results
Slide 15: Calls per Day
Calls per Day September’s 9.2 average calls per day reflects an 11% increase versus August and the highest level in the past 6 months Sources: Call Activity: Veeva - F2F calls only 15
Slide 16: % of Call Effort to Top Decile HCPs
% of Call Effort to Top Decile HCPs Decile 7-10 HCPs represented greater than 50% of all call efforts in September, aligning with rollout of a smaller, yet higher opportunity, target audience receiving increased frequency Sources: Call Activity: Veeva - F2F calls only Rx Decile: Symphony BCC Market
Slide 17: ANNOVERA Monthly TRx
ANNOVERA Monthly TRx Source: Symphony PHAST – September 2021 +14% vs. Prior 3 Months 17
Slide 18: ANNOVERA Quarterly TRx
ANNOVERA Quarterly TRx Source: Symphony PHAST – September 2021 +14% 18
Slide 19: ANNOVERA Prescribers: Launch to Date
ANNOVERA Prescribers: Launch to Date Source: Symphony PHAST – September 2021; 5 prescribers in Q319 New prescribers defined as not having written ANNOVERA in prior periods 19
Slide 20: IMVEXXY Quarterly TRx
IMVEXXY Quarterly TRx Source: Symphony PHAST – September 2021 Held up well considering prioritization on ANNOVERA in Q3 Full targeting and mix assessment to be completed Q4 2021 20
Slide 21: Accelerators for Q4 and Beyond
Accelerators for Q4 and Beyond Significant managed care wins Major sources of Prior Authorizations Increase covered lives by 14 million 1 2 3 1 J Code assigned Allows ANNOVERA access in Public Health sector 2 Twenty-two newly filled territories High potential areas In field first week of October 3 2
Slide 22: TherapeuticsMD - For Her. For Life.
TherapeuticsMD” For Her: For Life.